Skip to Main Navigation Skip to Page Content

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Target Organs and Levels of Evidence for TR-338

Toxicology and Carcinogenesis Studies of Erythromycin Stearate (CASRN 643-22-1) in F344/N Rats and B6C3F1 Mice (Feed Studies)

Chemical (Study Title) CASRN	Peer Review Date	Route/Exposure Levels	Study Laboratory
Erythromycin stearate 643-22-1	07/14/1987	Dosed-Feed R: 0,5000,10000 M: 0,2500,5000 PPM/50 PER GROUP	Physiological Research Laboratory

Levels of Evidence

Male Rats: No Evidence

Type	Organ/Tissue (Lesion)
Non-Neoplastic Lesions	LIVER: GRANULOMA 1/50 2/50 10/50

Female Rats: No Evidence

Type	Organ/Tissue (Lesion)
Non-Neoplastic Lesions	LIVER: GRANULOMA 18/50 27/50 43/50

Target Organs and Levels of Evidence for TR-338

Toxicology and Carcinogenesis Studies of Erythromycin Stearate (CASRN 643-22-1) in F344/N Rats and B6C3F1 Mice (Feed Studies)

Levels of Evidence

Male Rats: No Evidence

Female Rats: No Evidence

Male Mice: No Evidence

Female Mice: No Evidence